Skip to main content
. 2022 May 9;8:61. doi: 10.1038/s41523-022-00423-z

Fig. 2. Cumulative incidence curves for BCFi and OS by PAM50 subtypes.

Fig. 2

(a, b) All included patients, (c, d) patients with ER-positive/HER2-negative tumours, and (e, f) patients with available intrinsic PAM50 and surrogate subtyping by St. Gallen 2013. Overall P-values from log rank test, Gehan’s version for BCFi, for maximum follow-up and for different time intervals. BCFi breast cancer-free interval, HER2-E human epidermal growth factor receptor 2-enriched, Lum Luminal, OS overall survival, SC surrogate classification.